84 episodes
Oncology Brothers: Practice-Changing Cancer Discussions Oncology Brothers
-
- Health & Fitness
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
-
- video
GI Cancer ASCO 2024 Practice Changing Highlights - Discussion with Dr. Mark Lewis
Join Drs. Rohit Gosain and Rahul Gosain as they dive into the practice-changing updates from ASCO 2024 conference. In this episode, they are joined by Dr. Mark Lewis to cover key studies in GI malignancies from the conference.
In this episode, they discuss:• The ESOPEC study comparing concurrent chemoradiation versus periop FLOT regimen for upper GI adenocarcinoma.• The ARMANI trial on switch maintenance with ramucirumab plus paclitaxel.• The TRANSMET trial exploring chemotherapy followed by liver transplantation for metastatic liver-confined colorectal cancer.• The COLLISION trial comparing surgery versus ablation for small size colorectal liver metastatic disease.• The COMMIT study looking at the use of atezolizumab with chemotherapy in first-line treatment for MSI high metastatic colorectal cancer.These studies highlight the importance of biomarker testing and a multidisciplinary approach in the treatment of cancer.
Tune in to gain valuable insights from ASCO 2024 and stay informed about the latest advancements in oncology. Don't forget to check out their lung, GU, and breast cancer highlights from the conference as well.Stay connected with the Oncology Brothers for more updates and discussions on the latest in the world of oncology. Thank you for tuning in! -
- video
GU Cancer ASCO 2024 Practice Changing Highlights - Discussion with Dr. Toni Choueiri
Welcome to another insightful episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Toni Choueiri, a GU Medical Oncologist from Dana-Farber Cancer Institute, to discuss key abstracts from ASCO 2024.
They delve into topics such as the impact of the EV302 study on metastatic bladder cancer, the potential role of ctDNA as a biomarker in bladder cancer, real-world data on metastatic RCC, and the PSMA-4 study in prostate cancer. The discussion covers patient-reported outcomes, treatment strategies, and the evolving landscape of oncology care.
Tune in to gain valuable insights into the latest advancements in oncology and how they are shaping the standard of care for patients. Don't miss out on this engaging conversation with experts in the field. Subscribe to the Oncology Brothers podcast for more updates from the world of oncology.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com -
- video
Breast Cancer ASCO 2024 Practice Changing Highlights - Discussion with Dr. Erika Hamilton
Join the Oncology Brothers podcast as they dive into the highlights from ASCO 2024 with special guest Dr. Erika Hamilton, a breast medical oncologist from the Sarah Cannon Research Institute. In this episode, they discuss key abstracts in the world of breast cancer, including updates on RxPonder, PostMonarch, INAVO120, DESTINY-Breast06, and the Emerald Trial. Dr. Hamilton provides valuable insights on biomarker testing, CDK4/6 inhibitors, and groundbreaking advancements in HER2-targeted therapies. Discover how these studies are shaping treatment strategies for hormone receptor positive, HER2-low, and HER2-positive breast cancer patients. Don't miss out on this informative discussion packed with practical insights for community oncologists. Stay tuned for more ASCO 2024 highlights from the Oncology Brothers podcast.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com -
- video
Lung Cancer ASCO 2024 Practice Changing Highlights - Discussion with Dr. Joshua Sabari
In this episode, hosts Drs. Rahul and Rohit Gosain are joined by special guest Dr. Joshua Sabari, a thoracic medical oncologist from NYU Langone Health. Together, they dive into the highlights from ASCO 2024, focusing on key studies in lung cancer.Here's a quick summary of what you can expect in this episode:• LAURA Trial: Discussing the use of Osimertinib as a consolidation approach after chemoradiation in unresectable stage 3 non-small cell lung cancer patients with common EGFR mutation.• MARIPOSA Study: Exploring the potential of Amivantamab and Lazertinib in common EGFR mutations.• CROWN Study and other ALK inhibitors: Alectinib, Lorlatinib, and Brigatinib for metastatic non-small cell lung cancer.• ADRIATIC Study: Examining the use of Durvalumab after concurrent chemoradiation in limited-stage small cell lung cancer.
• PALOMA-3 Trial: Discussing subcutaneous Amivantamab vs. IV Amivantamab with Lazertinib
Join the Oncology Brothers and Dr. Sabari as they break down these practice-changing studies and provide insights into the latest advancements in lung cancer treatment. Don't miss out on this informative and engaging discussion!
Stay tuned for more ASCO 2024 highlights and updates on GI, GU, and breast cancer in the upcoming episodes. Subscribe to the Oncology Brothers Podcast for the latest in oncology news and research. Thank you for listening!
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com -
- video
Multidisciplinary Treatment Approach for Rectal Cancer - Discussion with Drs. Deb Schrag & Krishan Jethwa
Welcome to another insightful episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain delve into the world of locally advanced rectal cancer, focusing on the latest treatment strategies and advancements in the field.
Joined by esteemed guests Dr. Deborah Schrag, a medical oncologist from Memorial Sloan Kettering Cancer Center, and Dr. Krishan Jethwa, a radiation oncologist from the Mayo Clinic, the discussion centers around the groundbreaking Prospect study. This study challenges the traditional approach to rectal cancer treatment, emphasizing the importance of balancing therapeutic efficacy with minimizing chronic side effects.
The conversation covers a range of topics, from the utilization of different chemotherapy regimens to the evolving paradigm of radiation therapy. Dr. Schrag and Dr. Jethwa provide valuable insights into determining the optimal treatment course for patients with locally advanced rectal cancer, including the selective omission of surgery and the significance of MSI high status in treatment decisions.
Tune in to learn about the latest advancements in rectal cancer treatment, the implications of the Prospect study, and the importance of personalized, multidisciplinary approaches in oncology care. Don't miss out on this informative discussion that sheds light on the complexities of managing rectal cancer and the evolving treatment landscape.
Stay informed and up-to-date with the Oncology Brothers podcast as they continue to explore the dynamic world of oncology treatment. Subscribe now and join the conversation!
Guests:
Dr. Deborah Schrag, Medical Oncologist, Memorial Sloan Kettering Cancer Center
Dr. Krishan Jethwa, Radiation Oncologist, Mayo Clinic -
- video
Zanubrutinib - FDA Approval, Efficacy & Safety Profile in CLL - Discussion with Dr. Shadman
Join Rahul and Rohit Gosain, the Oncology Brothers, in this insightful podcast episode where they discuss the latest advancements in hematology and oncology. In this episode, they are joined by Dr. Mazyar Shadman from Fred Hutch Cancer Center to delve into the Sequoia and Alpine trials that led to the approval of Zanubrutinib in CLL.
Key Points Discussed:
• The Sequoia trial focused on Zanubrutinib in first-line CLL treatment, showcasing its superiority over traditional chemotherapy.
• The Alpine study compared Zanubrutinib to Ibrutinib in relapsed/refractory settings, demonstrating Zanubrutinib's efficacy and safety profile.
• Acalabrutinib and Zanubrutinib were indirectly compared in a post-analysis, shedding light on their differences.
• Dr. Shadman provides insights on managing common side effects of Zanubrutinib, highlighting its improved tolerability.
Tune in to this episode for a comprehensive discussion on Zanubrutinib in CLL, including trial outcomes, comparisons, and practical considerations for patient care. Stay informed with the Oncology Brothers as they navigate the evolving landscape of oncology treatments